Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients
Open Access
Abstract
Background Osteopontin (OPN) is a glycoprotein involved in Th1 and Th17 differentiation, tissue inflammation and remodelling. We explored the role of serum OPN (sOPN) as a biomarker in patients with giant cell arteritis (GCA). Methods sOPN was measured by immunoassay in 76 treatment-naïve patients with GCA and 25 age-matched and sex-matched controls. In 36 patients, a second measurement was performed after 1 year of glucocorticoid treatment. Baseline clinical and laboratory findings, as well as relapses and glucocorticoid requirements during follow-up, were prospectively recorded. sOPN and C reactive protein (CRP) were measured in 32 additional patients in remission treated with glucocorticoids or tocilizumab (interleukin 6 (IL-6) receptor antagonist). In cultured temporal arteries exposed and unexposed to tocilizumab, OPN mRNA expression and protein production were measured by reverse transcription polymerase chain reaction (RT-PCR) and immunoassay, respectively. Results sOPN concentration (ng/mL; mean±SD) was significantly elevated in patients with active disease (116.75±65.61) compared with controls (41.10±22.65; pConclusions sOPN is a marker of disease activity and a predictor of relapse in GCA. Since OPN is not exclusively IL-6-dependent, sOPN might be a suitable disease activity biomarker in tocilizumab-treated patients.Keywords
Funding Information
- European Regional Development Fund
- Ministerio de Economía y Competitividad
- Marató TV3
- Instituto de Salud Carlos III
This publication has 40 references indexed in Scilit:
- Elevated messenger RNA expression and plasma protein levels of osteopontin and matrix metalloproteinase types 2 and 9 in patients with ascending aortic aneurysmsThe Journal of Thoracic and Cardiovascular Surgery, 2013
- Relapses and Recurrences in Giant Cell ArteritisMedicine, 2011
- Osteopontin, intrinsic tissue regulator of intractable inflammatory diseasesPathology International, 2011
- NF-κB– and AP-1–Mediated DNA Looping Regulates Osteopontin Transcription in Endotoxin-Stimulated Murine MacrophagesThe Journal of Immunology, 2011
- Osteopontin in antineutrophil cytoplasmic autoantibody-associated vasculitis: relation to disease activity, organ manifestation and immunosuppressive therapyAnnals of the Rheumatic Diseases, 2010
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008
- OsteopontinArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomesArthritis Care & Research, 2003
- A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant‐cell arteritisArthritis Care & Research, 2002
- Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survivalJournal of Clinical Investigation, 2001